2025 Poster Presentations
Poster Awards will be announced Wednesday at 10:45 and Thursday at 13:30
POSTER SESSION A: Tuesday - Wednesday (morning)
*Poster 001 will be in both Poster Sessions but available Wednesday only.
*A001: Early Bystander Effect of Vaccine Boosting of CAR-T Cells Reinvigorates Endogenous Anti-Tumor T Cell Immunity to Regress Pancreatic Cancer, Presented by Leyuan M., Children's Hospital of Philadelphia
A002: High-Throughput Precision: mMPS Synthesis Technology for Advanced Antibody Variant Engineering, Presented by Alex PL., GCATBio
A003: Binding Kinetics Measured on Cells - Pain or Gain?, Presented by Vera M., 2bind GmbH
A004: Development of Antibodies as Tools for Combating Viral Infections, Presented by Irene DA., Aalborg University
A005: Preclinical Development of ABCL575, a Half-Life Extended Anti-OX40L Monoclonal Antibody for the Treatment of Autoimmune Conditions, Presented by Nik M., AbCellera
A006: Atlas™ Mice Provide a Differentiated Toolset for Generation of Human Therapeutic Antibodies Against Multi-Specific Targets and Buried Epitopes, Presented by Dan R., AbTherx
A007: High-Throughput Discovery of High-Affinity TCRs from Synthetic Yeast-Based Libraries, Presented by Tse-Han K., Adimab LLC
A008: Harnessing the Adimab platform: Case Studies Exemplifying Our Path from De Novo Discovery to Clinical Advancement, Presented by Bianka P., Adimab LLC
A009: Complementary Methodologies for Size Heterogeneity Analysis of Antibody Impurities, Presented by Xuemei L., Agilent Technologies
A010: CORYNEX®: A Highly Efficient Platform for Long-Chain Peptide/Protein Production, Presented by Kentaro N., Ajinomoto Co., Inc.
A011: Exploring Trastuzumab's Potential with a Mixed Organoid System for Tailored Therapeutics in Pancreatic Cancer, Presented by Jae-Il C., Ajou University
A012: Engineering IgG Antibodies for Intracellular Targeting and Drug Delivery, Presented by Sang Rok Y., Ajou University
A013: Skimune: An In Vitro Human Skin Platform for Immunotoxicity Testing of Novel Therapeutics, Presented by Steven O., Alcyomics Ltd.
A014: Mapping Antibody Behaviour: Multi-Dimensional Data for Developability, Presented by Alireza M., Apoha
A015: Immunology Innovation Program: Developing Antibodies to Novel Targets via Co-Creation, Presented by Julie V. & Bram V., argenx
A016: ARGX-109 Is a Humanized IgG1 Monoclonal Antibody that Binds IL-6 and Is Engineered to Achieve a Long Half-Life, Presented by Geil T., argenx
A017: Antibody Language Models for Hit Down-Selection in the Context of In Vivo Antibody Discovery, Presented by Marisol AM., AstraZeneca
A018: HIC Method Development for Fractions Enrichment and Collection of Mispaired Species Using AKTA System, Presented by Giordana L., AstraZeneca
A019: Proximity-Driven Site-Specific Cyclization of Phage-Displayed Peptides, Presented by Carole U., AstraZeneca
A020: Atbodies: Weaponised Antibodies with Distinct Mechanisms of Action Produced in a Single Step, Presented by Sebastien M., Atbtherapeutics
A021: Advancing Therapeutic Protein and Vaccine Development with High-Throughput Signal Peptide Engineering, Presented by Katja R., Avenue Biosciences
A022: Tackling the Specificity Challenge in the Generation of Peptide-MHC Binding Fragments for CAR-T-Based Therapeutics, Presented by Nienke S., AVS Bio
A023: Characterization of an Antibody – Target Interaction Using Flow Induced Dispersion Analysis, Presented by Daniel W., Bayer Pharma AG
A024: The Bicycle® Platform: An Efficient Technology to Generate High Affinity, High Selectivity Molecules that Are Amenable to Conjugation, Presented by Harry K., Bicycle Therapeutics
A025: BDKcell™: An Efficient Stable Cell Line Development Platform, Presented by Emma Z., BioDlink
A026: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Leon S., Biointron
A027: Speed Counts While Quality Matters: A Fast-Track Approach to Bispecific Antibody Production, Presented by Lei S., Biointron
A028: High-Affinity Antibodies for Fentanyl Detection: Innovations in Phage Display Technology, Presented by Romain P., bioMerieux
A029: Advancing Forced Degradation Studies: Design of Experiments for Enhanced Structure-Function Relationship Analysis in Biotherapeutics, Presented by Klaus K., Boehringer Ingelheim Pharma GmbH & Co. KG
A030: Identification of Critical Reagent Leads Using High-Throughput SPR, Presented by Andrew G., Carterra, Inc.
A031: Development of a New Quantitative Two Hybrid System with Original Applications in Protein and Antibody Engineering, Presented by Antoine G., CEA - French Alternative Energies and Atomic Energy Commission
A032: Safety Profile Assessment for IND-Enabling Studies: Bispecific Antibodies and Antibody-Drug Conjugates (ADCs), Presented by Lisa S., Charles River Laboratories
A033: Structure-Based Charge Calculations for Predicting Properties and Profiling Antibody Therapeutics, Presented by Nels T., Chemical Computing Group
A034: Monitoring of Buffer Exchange and Protein Concentration During UF/DF Using a Novel Multi Attribute Method, Presented by Janosch A., CLADE GmbH
A035: ADVANCING MYCOPLASMA DETECTION: Compendial & Alternative Methods in a Changing Regulatory Landscape, Presented by Alexis R., Clean Cells
A036: A Function-First ML-Guided High Throughput Screening Platform for the Discovery of VHH-Based T-Cell Engagers, Presented by Edward K., Coding Bio Ltd.
A037: DIANA-Ab: Novel Technology for Monoclonal Antibody Development, Presented by Daniela G., DIANA Biotechnologies
A038: High-Throughput Antibody Structure and Ensemble Protein Property Predictions, Presented by Meline S., Discngine SAS
A039: Development of Antibody Mass Production Technology Using Rice Seeds, Presented by Yuta S., Ehime University
A040: AI In-Silico Screening Improves the Success Rate of Recombinant Protein Production, Presented by Evgeny T., EMBL-EBI (European Molecular Biology Laboratory)
A041: Hybrid IgE-IgG1 Antibodies (IgEG): A New Antibody Class that Combines IgE and IgG Functionality, Presented by John D., Epsilogen Ltd.
A042: Unlocking Agonism: A Comprehensive Strategy to Characterize Agonistic Antibodies for Immunotherapy and Autoimmunity, Presented by Alpana P., Eurofins DiscoverX
A043: Streamlining Bioprocesses by Converting a Dual-Feed into a Single-Feed System with Peptides, Presented by Catrin H., Evonik
A044: Combination with a Novel Costimulatory CD2 Bispecific Antibody Overcomes Limitations of CD3 T Cell Engager Treatment for Solid Tumors, Presented by Welbeck D., Evotec International GmbH
A045: MytomAb: Next-Level Efficacy for Tumor Cell-Targeted Antibody Drugs, Presented by Priyanka S., Evotec International GmbH
A046: From Binding to Biology: Assessing Fc–FcRn and Fc–FcγR Interactions to Drive Antibody Fc Design, Presented by Silvestre L., FairJourney Biologics
A047: Beyond Binding: Functional Cell-Based Assays to Unveil and Accelerate the Path from Discovery to Therapeutic Success, Presented by Sara L., FairJourney Biologics
A048: Use of Transgenic Animals and NGS to Accelerate Antibody Discovery, Presented by Joana Q., FairJourney Biologics
A049: Characterizing Multivalent Complex Formation Using Controlled Complex Lifetime with FIDA, Presented by Henrik J., Fida Biosystems ApS
A050: Ready-to-Click Nanobodies Enabled by Mammalian Cell-Free Platforms, Presented by Anne Z., Fraunhofer Institute for Cell Therapy and Immunology
A051: Generation and Characterization of Human Anti-YFV Monoclonal Antibodies from YF17D Booster Vaccinated Individuals, Presented by Sabine S., Fraunhofer Institute for Translational Medicine and Pharmacology
A052: OptiMAL: Mammalian Display for Antibody Discovery, Presented by Simon L., Fusion Antibodies
A053: Automated Analysis of High-Throughput Protein Stability for Antibody Developability Assessment, Presented by Moritz P., Genedata AG
A054: High-Throughput Mass Spectrometry Analytics for ML/AI-Ready Drug Discovery, Presented by Laura RP., Genedata AG
A055: Antibody and Therapeutics Discovery: Interrogating Large NGS Datasets, Presented by Monica W., Geneious
A056: Comprehensive Developability Profiling of 860 VHH-Fc Constructs for Predictive Stability Modeling, Presented by Nicole DH., Genmab
A057: Enzymatic Strategies for Reliable and Site-Specific ADC Generation, Presented by Philip W., Genovis
A058: Driving Efficiency in Antibody Production: Strategies for Optimizing Expression and Purification, Presented by Tong S., GenScript
A059: Bioanalytics for Mispairing Profiling of Multispecific Antibodies: Impact on Bioprocess Design, Presented by Sofia C., iBET Instituto de Biologia Experimental Tecnologica
A060: Assessing Omic Mispairing Signatures in Chinese Hamster Ovary (CHO) Cells Producing a Tri-Specific Antibody, Presented by Patricia GA., iBET Instituto de Biologia Experimental Tecnologica
A061: High-Sensitivity MAPPs for Immunogenicity Risk Assessment of Biotherapeutics, Presented by Ellen B., ImmuneSpec
A062: Investigating the Determinants of TCR Cell Surface Expression with Mammalian Display and NGS, Presented by Gianluca V., Immunocore Ltd.
A063: CHO Landing Pads for Super-Fast Generation of Stable Recombinant Cell Lines, Presented by Tobias M., InSCREENeX GmbH
A064: Epitope Evaluation of Antibody Libraries Using Mammalian Cell Display, Presented by Tetsuya K., Institute of Science Tokyo
A065: A New Approach Methodology (NAM) for Specificity Testing: ISTAND Qualification of the Membrane Proteome Array to Evaluate Off-Target Binding of MAb-Based Therapies, Presented by Rachel F., Integral Molecular
A066: CDR-Scanning for Antibody Engineering and Species Cross-Reactivity, Presented by Sharon W., Integral Molecular
A067: Unleashing the Power of MHC-Associated Peptide Proteomics: Immunogenicity Assessment of Biotherapeutics, Presented by Chloe A., IQVIA Labs
A068: Next-Generation Conjugates – Site Specific Conjugation of VHH Antibody Modalities, Presented by Lurdes D., Isogenica
A069: HuPK™: An In Vivo Platform Replacing Non-Human Primates for Preclinical Antibody PK Testing, Presented by Adriano F., Jackson Laboratory
A070: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Anil K., KACTUS
A071: GPCR VLPs & Nanodiscs for Drug Discovery, Presented by Manhee S., KACTUS
A072: GMP VHH Platform for Rapid Tox and Clinical Access, Presented by Céline R., Kaneka Eurogentec
A073: Characteristics for Retargeting Retroviral Vectors Using Nanobodies, Presented by Pieterjan V., KU Leuven
A074: Advancing Biologics Development with an Integrated Analytical Toolbox, Presented by Ziva R., Labena doo
A075: Vaccine Design Using Graph Convolutional Neural Networks - Stabilizing Viral Glycoproteins by Mutating Amino Acids to Proline Residues, Presented by Jakob R., Leipzig University
A076: Rapid Acceleration of Multispecific Ab Discovery and Development Using Eukaryotic Cell-Free Expression System, Presented by Sara K., LenioBio GmbH
A077: Biophysical Blueprint: Building Tools that Drive Biotherapeutic Progression, Presented by Han Y., LifeArc
A078: Envisia: Advancing Antibody Discovery with Single-Cell, Function-Focused Profiling, Presented by Simon M., Lightcast
A079: High-Throughput Antibody Discovery Workflow to Select the Rarest High-Affinity Clones, Presented by Natacha C., LiveDrop
A080: Avidion™: High-Throughput Cell Binding Avidity Platform for Screening Cell Engagers, Multispecific Antibodies, and Cell Therapies, Presented by Brittany W., LUMICKS
A081: Biosimilar Case Study, Presented by Mun Ching L., MabPlex
A082: Harnessing the Tumor Microenvironment: Converting hurdles into Opportunities for innovative therapeutic antibodies, Presented by Anne C., Mabqi
A083: MY006: Engineering of an Anti-Peanut Allergen Multispecific Antibody for the Treatment of Peanut Allergy, Presented by Rahel S., Mabylon
A084: Improving Protein Stability Through Deep Learning Method: The AIACCLBIO™ Platform, Presented by Song L., Matwings Technology
A085: MACS® Matchmaker: Biomolecular Interaction Analysis in Real Samples, Presented by Volker N., Miltenyi Biotec B.V. & Co. KG
A086: The MHC MACSimer Technology Combines Flexibility and Releasability for the Detection of Antigen Specific T Cells, Presented by Lukas K., Miltenyi Biotec B.V. & Co. KG
A087: Discovery, Analysis and Enrichment of Antigen-Specific T Cells to Advance the Development of TCR-Based Therapies by Using MHC MACSimer Reagents, Presented by Lennart W., Miltenyi Biotec B.V. & Co. KG
A088: A Comprehensive Discovery and Engineering Workflow for Developing Innovative Anti-Nectin-4 Antibody Drug Conjugates, Presented by Jacques F., MImAbs
A089: Rapid Single-Cell Discovery of Tumor-Targeting Antibodies Using the Bruker Beacon® Platform for Therapeutic Development, Presented by Marie H., MImAbs
A090: A Novel mRNA Delivery Vector for Eukaryotic Cells Produced in Bacteria, Presented by Carlos C., National Autonomous University of Mexico (UNAM)
A091: Deep Learning of Antibody Epitopes Using Positional Permutation Vectors, Presented by Lluis A., NEC OncoImmunity AS
A092: Self-Removing Purification Tags Based On Split Inteins: A Promising Technology, Presented by Angelica B., Novartis Pharma AG
A093: Accelerated Antibody Optimization: Using NGS and Structural Prediction to Guide Affinity Maturation, Presented by Jonas J., Novo Nordisk A/S
A094: Advanced Raman Spectroscopy for Detection of Contaminants in Non-Transparent Formulations, Presented by Jesper S., Novo Nordisk A/S
A095: Screen, Scale, Capture, Characterize: Rapid Protein Production and Characterization of Drug-Target Interactions, Presented by Kundan S., Nuclera
A096: Functional Membrane Proteins - Ready in 48 Hours, Presented by Ruben T., Nuclera
A097: A New Layer of Developability Screenings with the PAIA Microplate Technology: The pH-Dependent FcRn Binding and Release Assay, Presented by Annika R., PAIA Biotech GmbH
A098: Comprehensive Analytical Toolbox for mAb CQA Assessment: A Forced Degradation Case Study, Presented by John A., Pharmaron
A099: Preclinical Development of a VHH-ADC Using the Pfenex Platform, Presented by Diane R., Primrose Bio
A100: Overcoming Limitations of Constitutive Protein Expression with the Power of Optogenetics, Presented by Kiana MS., Prolific Machines
A101: Binding to Bridging: Complete Suite of FcγR Assay Tools Accelerates Antibody Therapeutic Development, Presented by Steven E., Promega Corporation
A102: Nanobody-Based Tools for In-Depth Research of Immuno-Oncology Targets, Presented by Philipp B. & Simon S., Proteintech Germany GmbH
A103: Smart and Efficient Antibody Design Online, Presented by Misaki O., RevolKa
A104: CHOSOURCE™ Transposon Technology: Enhancing Speed, Stability, and Productivity, Presented by Amanda J., Revvity
A105: From GS KO to ADCC+: Expanding the CHOSOURCE™ Expression Platform for High-Potency Therapeutic Antibodies, Presented by Alex O., Revvity
A106: Characterization of Cetuximab Charge Variants by Direct Coupling of Capillary Isoelectric Focusing with Mass Spectrometry, Presented by Pieter-Paul S., RIC biologics
A107: Avidity Effects of CD20 Antibodies on Live Cells, Presented by Sina B., Ridgeview Instruments AB
A108: Analytical Strategies for Characterization of Antibody-Oligonucleotide Conjugates, Presented by Maximiliane K., Roche Diagnostics GmbH
A109: HCLF-Enabling Developability Assessment - How Molecule Characterization Supports Molecule to Drug Transition, Presented by Jasmin SA., Roche Diagnostics GmbH
A110: CHO Cell-Free Expression Driven by Mitochondrial Respiration, Presented by Maximilian G., RWTH Aachen
A111: Advancing Drug Discovery: Integrating 3D Spheroid Models and Live-Cell Analysis for Compound Screening, Presented by Attila A., Sartorius Lab Instruments GmbH & Co. KG
A112: Unveiling Hidden Insights: Enhanced Analytics with Octet® BLI R8e, Presented by Ivan K., Sartorius Lab Instruments GmbH & Co. KG
A113: Development of a Chicken Immunoglobulin Heavy Chain Variable Region (VH) Single Domain Antibody (sdAb) Against Calsequestrin (CSQ) and Its Application, Presented by Eunjae L., Seoul National University
A114: A New Form of Protein Aggregates: An Early Warning Sign of Polysorbate Degradation, Presented by Laura P., Spheryx, Inc.
A115: Pro-PBD ADCs: Optimization of Therapeutic Potential of ADCs Based on Capped PBD Payload with Attenuated Potency, Presented by Mick V., Synaffix B.V.
A116: TCX-201, a Novel ADC Targeting a Specific Tumor-Associated Carbohydrate Antigen (TACA) with Excellent Preclinical Efficacy, PK and Safety Profile in Solid Tumor Models, Presented by Francesco M., Tacalyx GmbH
A117: Automated Sample Preparation for In-Depth Plasma Proteomics, Presented by Jana L., Tecan
A118: A Masking Clamp for Conditional Activation of Therapeutic Antibodies, Presented by Adrian B., Technical University of Darmstadt
A119: Antibody-Degrader-Conjugates: Promising New Therapeutics for Cancer Treatment, Presented by Alessandro E., Technical University of Darmstadt
A120: Computational Prediction of VHH Aggregation Propensities Facilitates Discovery and Humanization of Recombinant Nanobodies, Presented by Felix G., Technical University of Darmstadt
A121: Expi293™PRO Expression System: A Next-Generation Expression System for Higher Yields Across a Wider Variety of Proteins, Presented by Chao Yan L., Thermo Fisher Scientific
A122: Expi293™ PRO Expression System: Expression Improvements Across Different Classes of Proteins, Product Quality Assessment and Automated Purification, Presented by Nan Y., Thermo Fisher Scientific
A123: Enhancing the Cytotoxicity of T-Cell Engaging Antibodies Against Cancer Cells Using Machine Learning Assistance, Presented by Tomoyuki I., Tohoku University
A124: Antibody Discovery from Immune VHH Library Using Yeast Surface Display, Presented by Hao G., Twist Bioscience
A125: Rapid Discovery of Hundreds of Rabbit mAbs with High Affinity and Cell Binding Against CD19 Utilizing the Beacon Optofluidic Platform, Presented by Lynette T., Twist Bioscience
A126: Computational Approaches to Target Glyco-Immune Checkpoints in CAR T-Cell: Opportunities for Novel Small-Molecule Therapeutics, Presented by Patricia S., Universidade NOVA de Lisboa
A127: Deep Sequencing Analysis of Phage Display Biopanning Against CXCR4 on Disease and Model Cells, Presented by Cian M., University College Dublin
A128: Selection of GLP-1R Agonists from a Novel Library Using Phage Display, Presented by Jamie P., University College Dublin
A129: Engineering a Human Deacylase for Targeted Bio-Orthogonal Prodrug Activation, Presented by Yannick B., University of Applied Sciences Darmstadt
A130: Generating Novel Recombinant Antibodies Targeting Phospholipase A2 from Spitting Cobras, Presented by Sheikh A., University of Cambridge
A131: SurfDiff: Rational Epitope Prioritisation for Translational Binder Design, Presented by Benedikt J., University of Cambridge
A132: GMP-Compatible Adenine Base Editing Strategy for Highly Efficient Gene Knockout in Tumor Infiltrating Lymphocytes, Presented by Melita I., University of Lausanne
A133: A Rabbit-Derived Single-Domain Antibody Fused to the Streptococcus zooepidemicus Zag Protein for Potent SARS-CoV-2 Neutralization and Extended Half-Life, Presented by Isa M., University of Lisbon
A134: Analysis of Pareto Optimality at the Antibody-Antigen Interface, Presented by Tadej M., University of Ljubljana
A135: A Phagocytosis Assay to Test Internalization of Mutated HTT-Ab Complexes in the Monocytic Cell Line THP-1, Presented by Veronica N., University of Natural Resources and Life Sciences - BOKU
A136: Yeast Display-Based Affinity Maturation of Humanized Antibodies for Huntington’s Disease Therapy, Presented by Paul P., University of Natural Resources and Life Sciences - BOKU
A137: Tethered Neutralizing Antibodies (tNAbs) for Lung Antiviral Defence, Presented by Alex N., University of Oxford
A138: RING 4.0: Decoding Protein Structure with Residue Interaction Networks, Presented by Sol Clara B., University of Padua
A139: NG2/CSPG4: A Promising Target in Gastric Cancer, Presented by Silvia S., University of Parma
A140: Development and Validation of an Anti-COMP Antibody for Potential Diagnostic and Therapeutic Use in Canine Soft Tissue Sarcoma, Presented by Graziana T., University of Parma
A141: Re-Wiring HEK293 Cells to Enhance Transient Protein Production, Presented by Farah A., University of Sheffield
A142: Breaking New Ground: CHO Cells in Perfusion Bioreactors Show Transcriptional Reprogramming and Genomic Instability, Presented by Noah H., University of Sheffield
A143: Applications of IgNAR Antibodies Derived from Shark, Pioneering Next-Generation Cancer Antibody Therapeutics, Presented by Yuki N., University of Tokyo
A144: A New Approach to Examine Cell Avidity and Affinity with Surface Plasmon Resonance, Presented by Richard S., University of Twente
A145: Micro Developability: High-Throughput Developability Assessment for Early-Stage Lead Optimization, Presented by Antony C., WuXi Biologics
A146: Developing Rabbit mAbs Against Difficult Targets, Presented by Jieying L., WuXi Biologics
A147: T Cell Mate: An Innovative High-Titer CHO Platform Setting a New Standard for T-Cell-Related Protein Production, Presented by Chunsu X., WuXi Biologics
A148: Novel Conjugation and Payload-Linker Technologies for Next Generation ADCs, Presented by Jo V., WuXi XDC
POSTER SESSION B: Wednesday (afternoon) - Thursday
*Poster 001 will be in both Poster Sessions but available Wednesday only.
*B001: Early Bystander Effect of Vaccine Boosting of CAR-T Cells Reinvigorates Endogenous Anti-Tumor T Cell Immunity to Regress Pancreatic Cancer, Presented by Leyuan M., Children's Hospital of Philadelphia
B002: Development of a Versatile Microbial Platform for Rapid Production and Purification of VHH Antibodies, Presented by Quentin N., Kaneka Eurogentec
B003: Opti-mAb: A Novel scFv Format for Improved Therapies, Presented by Daniel J., AAX Biotech
B004: In Silico Strategies for Antibody Development at Abcam, Presented by Vivian M., Abcam
B005: Bioanalytical QC of Antibody Oligo Conjugates (AOCs), Presented by Marcel T., Abcam
B006: AbiLeap™: A Platform to Build Logic Gated Immune Engagers, Presented by Jean-Philippe B., Ability Biologics
B007: Rapid Discovery and Optimization of Functional Membrane Protein-Specific Antibodies by Coupling In Vivo Diversities with a Yeast-Based Platform, Presented by Meriah D., Adimab LLC
B008: AI-Powered Rare Hit Identification Through Immune Repertoire Mining, Presented by Kyle K., Ailux, a XtalPi Company
B009: AI-Guided Multispecific Antibody Design: scFv, Common Light Chain, and Two-in-One, Presented by Mary Ann P., Ailux, a XtalPi Company
B010: AI-Guided De Novo Design of Domain-Specific Antibodies for a Transmembrane Protein, Presented by Gherici H., Antiverse
B011: Unifying Experimental Developability Data with In Silico Predictions to Accelerate Therapeutic Antibody Discovery, Presented by Vivek R., Apoha
B012: Targeting Nectin-4 with a First-in-Class Triple MMAE/Dual TOP1i Payload ADC Showing Synergistic Activity and Favorable Tolerability, Presented by Tanja L., Araris Biotech AG
B013: Increasing the Degradative Capacity of an FcRn-Enhanced Sweeping Antibody by Making It One-Armed, Presented by Maximilian B., argenx
B014: Rational Design and Engineering of Next-Generation FcRn Blockers for Prolonged IgG Depletion, Presented by Jolien V., argenx
B015: Allomorphic[ANTIBODY]: An End-to-End In Silico Framework for Rational Antibody Design, Presented by Injae C., Arontier Co., Ltd.
B016: AZD1163: First-in-Class Anti-PAD2/4 Bi-Specific Antibody to Inhibit Autoantigen Formation in Rheumatoid Arthritis, Presented by Juan B., AstraZeneca
B017: Unveiling Biomolecular Interactions: Integrating Structural Biology, Biophysics, and Mass Spectrometry Technologies, Presented by Noemi M., AstraZeneca
B018: Characterisation of Virus-Like Particles Displaying Complex Membrane Proteins Using Flow Virometry, Presented by Maria T., AstraZeneca
B019: Harnessing Diversity-Focused Mouse B Cell Discovery and Early Stage, High-Throughput Characterization for Rapid Functional Antibody Identification, Presented by Ilse R., AVS Bio
B020: Fully Automated Evotip Loading on the Biomek i-Series Workstation for Effortless and Seamless Scalability, Presented by Rene G., Beckman Coulter GmbH
B021: Analytical Tools and Strategy for Detecting Amino Acid Exchanges in Drug Substances, Presented by Benjamin M., Biofidus AG
B022: AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution, Presented by Boris X., Biointron
B023: Expression of Biotherapeuctics in BION-CHO™ and Establishment of Fed-Batch and Intensified Production Processes in AMBR®250, Presented by Alexandra B., Bioneer
B024: Physiologically Relevant 3D Tumor Heterospheroid Models with Fibroblasts and Macrophages for Anticancer Drug and Immunotherapy Screening, Presented by Natasha HM., Bioneer
B025: Accelerating Biologics Discovery with Comprehensive Biophysical Characterizations of Binding Kinetics, Presented by Sven M., Bruker
B026: Identifying an Appropriate Expression Host for Your Target: 3 Case Studies, Presented by Edward W., Cancer Research Horizons
B027: New Approach Methodologies (NAMs): Retrogenix® Technology for Rapid Early-Stage High-Throughput Screening and Toxicology Species Selection, Presented by Diogo R., Charles River Laboratories
B028: Pharmacophore-Guided Virtual Screening of Antibody Formats, Presented by Purvi G., Chemical Computing Group
B029: ML-Guided Hit Identification of Poly-Specific Nanobodies Against Snake Venom Toxins, Presented by Nicolo B., Cradle Bio
B030: Automated, ML-Driven Multi-Property Protein Lead Optimization, Presented by Jonathan Z., Cradle Bio
B031: A New Era for Full-Length Membrane Targets: From Lysate to Structure- and Assay-Ready Protein in 45 Minutes, Presented by Alexandra N., Cube Biotech GmbH
B032: High-Performance Antibody Discovery Using DPBIO CytoSpark Microfluidic Droplet Sorting System, Presented by Jennifer S., Dapu Biotechnology Co., Ltd. (DPBIO)
B033: Closing the Loop: Data-Powered Therapeutic Design with AI and Automation, Presented by Nikolay D., Data Powered Therapeutics GmbH
B034: Epitope Mapping Case Studies by Deep Mutational Scanning, Presented by Hugo G., Deeptope
B035: Modulation of Antibodies' Fc Fragment Interaction with Fc Receptors by Deep Mutational Scanning, Presented by Fabien Q., Deeptope
B036: Advancing Protein Engineering with Cas-CLOVER Host Cell Editing, Presented by Thomas H., Demeetra
B037: Covalently Controlled Conditional Immunocytokine Cancer Therapy: Silent in the Periphery and Super Active in the Tumor, Presented by Sue T., Depth Charge SAS
B038: RedQueen: Accelerating Antibody Paratope Design with Digital Directed Evolution, Presented by Georg R., Discovery Evolution
B039: Quantitative Detection of Residual CHO Cell DNA to Align with Bioprocess Chemistry, Manufacturing, and Control Regulatory and Quality Guidelines, Presented by Morgan M., Enzo Life Sciences
B040: Predicting Antibody Binding Affinity Across Millions of Variants Using High-Throughput Titration-Seq and Probabilistic Machine Learning, Presented by Ningning C., ETH Zurich
B041: Solutions for the Bispecific Antibody Mispairing Challenge in Preclinical R&D, Presented by Brad G., evitria AG
B042: Advancing Next-Generation Antibody Therapeutics Purification with High-Affinity Resins, Presented by Teresa B., FairJourney Biologics
B043: Acceleration of Biocatalyst Development Through Cell-Free Protein Synthesis: A Case Study on Unspecific Peroxygenases, Presented by Ruben W., Fraunhofer Institute for Cell Therapy and Immunology
B044: Establishment of Rabbit Monoclonal Antibodies Against Membrane Proteins Using New Single B Cell Screening Technology, Presented by Albert Z., FUJIFILM
B045: In Vitro PBMC-Based Model for Assessment of Vaccine Immunogenicity, Presented by Amanda C., FyoniBio GmbH
B046: Second Generation BLI as Tool for Protein Engineering, Presented by Diones B., Gator Bio
B047: Characterization of CD20 Biosimilars Using High-Quality Full-Length Antigens and Second-Generation Biolayer Interferometry, Presented by Stephan K., Gator Bio
B048: An Automated High Throughput Engineering Platform for AI-Supported Developability Predictions, Presented by Sebastian K., Genedata AG
B049: Accelerating Antibody Discovery: High-Throughput Solutions for Producing Antibodies at Scale, Presented by Prassanna R., GENEWIZ From Azenta Life Sciences
B050: Hingefluence: The Role of IgG Subclass Hinge Variations in Modulating Antibody-Mediated Effector Functions, Presented by Jana K., Genmab
B051: Label-Free Antibody Characterization on Challenging Targets, Presented by Dennis V., Genmab
B052: Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates, Presented by Matt W., Genovac Antibody Discovery LLC
B053: Middle-Level Mass Spectrometry Analysis of Chain Mispairing in Hinge-Mutated Bispecific Antibodies, Presented by Jantje M., Genovis
B054: Enhancing Antibody Quality and Developability with Optimized Protein Solutions, Presented by Amanda G., GenScript
B055: Innovative Hovione Synthetic Sugars for Enhanced Stability in High-Concentration Biologic Formulations, Presented by Margarida F., Hovione FarmaCiencia S.A.
B056: Optimizing Inhalation of a Monoclonal Antibody: Transitioning from Nebulizer to a Dry Powder Inhaler, Presented by Paulo L., Hovione FarmaCiencia S.A.
B057: Enabling Next-Generation Poliovirus VLP Vaccines Through Bioprocess Engineering, Presented by Rute C., iBET Instituto de Biologia Experimental Tecnologica
B058: BEAT®: A Platform to Advance Developable Multispecific Therapeutic Antibodies to the Clinic, Presented by Sebastian G., Ichnos Glenmark Innovation
B059: Unlocking the Power of Machine Learning for Codon Optimization and Predictable Protein Expression, Presented by Rita C., Ingenza Ltd.
B060: Camelid Cell Lines Expressing Membrane Complexes for VHH Generation, Presented by Kristina N., InSCREENeX GmbH
B061: Analyses of Monoclonal Antibody-Antigen Interaction by Circular Dichroism, Presented by Ana Maria M., Instituto Butantan
B062: Pan-Reactive mAbs Enable Preclinical Animal Models: High-Quality mAb Reagents for Hitting Targets in Diverse Animal Species, Presented by Ross C., Integral Molecular
B063: TPIPE, a Pipeline for the Identification and Functional Assessment of Therapeutic Cancer Vaccine Candidates, Presented by Sofie P., IQVIA Labs
B064: Small Is Beautiful – VHHs Enable Multi-Specific Targeting for Tandem-CAR Therapies, Presented by Marion C., Isogenica
B065: Evaluating NK Cell-Engaging Antibodies In Vivo, Presented by Ralph G., Jackson Laboratory
B066: A Humanized FcRn x Albumin Model to Assess HSA-Fused Therapeutic Candidates and FcRn Antagonists, Presented by Philip G., Jackson Laboratory
B067: Detection of AGEs in CEInfinite Fractionated Acidic Isoforms, Presented by Caleen D., Johnson & Johnson
B068: B Cell TuLibs: Immortalized Tumor-Derived B Cell Libraries for the Interrogation and Unbiased Discovery of Novel Therapeutic Targets and Antibodies from Patients, Presented by Alessandra V. & Casper M., Kling Biotherapeutics BV
B069: Screening of Antibodies Targeting Francisella tularensis Outer Membrane Protein A for Highly Sensitive Detection of Tularemia, Presented by Jieun J., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
B070: ADAPTs with Tailored Albumin Binding for Targeted Therapy and In Vivo Imaging of Ovarian Cancer, Presented by Emma L., KTH Royal Institute of Technology
B071: From Weeks to Days: Turbocharging High-Throughput Antibody Discovery Powered by ALiCE® for HTPE, Presented by Maja L., LenioBio GmbH
B072: Identification of Novel Signal Peptides for Improved mAb Expression Using an Automated High-Throughput Screening Process, Presented by Theo M., Lonza
B073: Generating Novel Target Cell Lines for Bespoke Bioassays: Reducing Timelines for Assessing Potency and Efficacy of Therapeutic Antibodies, Presented by Emma W., Lonza
B074: Kinetic Analysis of Nanobody Binding to Integral Membrane Proteins on Extracellular Vesicles, Presented by Gonda B., Malvern Panalytical
B075: Beyond Counting – Chemical Identification of SVPs with MDRS, Presented by John S., Malvern Panalytical
B076: Establishing an Integrated Platform for AI- Guided Miniprotein Design and Cell-Free Expression, Presented by Marten B., Mario Negri Institute for Pharmacological Research
B077: A Proteotranscriptomic Approach to Generate Monoclonal Antibodies by LC-MS/MS and Single Cell BCR Sequencing, Presented by Miriam D., Miltenyi Biotec B.V. & Co. KG
B078: Development and Optimization of an Anti-PD-1 sdAb/IL-12 Immunocytokine for Cancer Therapy, Presented by Noelia S., NanoGrow Biotech
B079: In Silico Is "OIL" You Need: Predicting Drug-Silicone Oil Interactions in Pre-Filled Syringes Using Molecular Modelling, Presented by Dimitra S., National Institute of Chemistry, Slovenia
B080: Robust TCR Production for the Structural Studies of TCR-pMHC Complexes, Presented by Leire O., Navarrabiomed - Centro de Investigación Biomédica
B081: Development of Fully Human Anti-CD98hc Antibodies to Enhance Delivery of Therapeutic Drugs Across the Blood-Brain Barrier, Presented by Zhiqiang W., NeoMab Biotechnology Co., Ltd.
B082: A Human In Vitro Secondary Lymphoid Organ Model to Advance Immune-Modulatory Drug Development, Presented by Courteney A., Nexus BioQuest Ltd.
B083: Discovery and Preclinical Validation of A Novel Enzyme-Cleavable Linker for TME-Specific Payload Release, Presented by Xiangyu R., Nona Biosciences
B084: Towards Industrial VHH Developability Characterization and HTP Screening, Presented by Christian P., Novo Nordisk A/S
B085: Numaswitch - A Novel Biochemical Platform for Efficient Peptide and Protein Production, Presented by Christian S., NUMAFERM GmbH
B086: Antigen Presenting Cell-Targeted Vaccines Show Durable Antigen-Specific Immune Tolerance in Mouse Models of Autoimmune Disease, Presented by Anthony R., Nykode Therapeutics
B087: Extensive Developability Profiling of a Diverse mAb Panel – From Biophysical Insight to PK Prediction, Presented by Aris P., PAIA Biotech GmbH
B088: Logic-Gated T Cell Engagers for Precision Cancer Therapy, Presented by Benjamin K., Plectonic Logibody GmbH
B089: Utilization of Naive VHH Library to Generate Ab Leads for CAR-T Therapy, Presented by Payal R., ProBio
B090: ProSpeed™ Single B Cell Ab Discovery, Presented by Nicolas S., ProBio
B091: Smart Automation and DirectedLuck® Transposase: Faster Selection of Producer Clones with Superior Quality, Presented by Thomas R., ProBioGen AG
B092: ANKYRONS - Next Generation Target Binding and Detection, Presented by Jeremy F., ProImmune, Inc.
B093: Dedicated Computational Methods for Feature Detection and Quantification in Large Molecule Mass Spectrometry Analyses, Presented by Vahid G., Protein Metrics, Inc.
B094: Protein-Centric Quantitation with Byos and GraphPad Prism, Presented by David L., Protein Metrics, Inc.
B095: Therapeutic Protein Charge Variant Characterisation with Intact Mass and Peptide Mapping Following Microgram Preparative Imaged Capillary Isoelectric Focusing Electrophoresis (icIEF) Fractionation, Presented by Cecile M., Quality Assistance
B096: Expediting Nanobody Development with De Novo Polyclonal Sequencing and Characterization with HDX-MS and SPR, Presented by Marko J., Rapid Novor
B097: A Novel De Novo Protein Sequencing Platform for Selective Anti-Idiotype Antibody Discovery, Presented by Iain R., Rapid Novor
B098: Advancing Biotherapeutic Manufacturing Through Precision Gene Editing Platforms, Presented by Neha M., Revvity
B099: Single-Cell Atlas-Guided Pair Selection for Enhanced Tumor Selectivity in Dual-Targeting Biologics, Presented by Emilio Y., Roche Innovation Center Zurich
B100: IndEx-2: An Inducible Cell Line Platform to Evaluate the Impact of Target Antigen Density on Immunotherapeutics, Presented by Andrea B., RoukenBio
B101: Antigen Specific T Cells for Assessing Immune Modulating Therapeutics, Presented by Matthew F., RoukenBio
B102: Discovery and Characterization of Antibodies against Challenging Membrane Protein Targets Using Salipro® Nano-Membrane Particles, Presented by Peter J., Salipro Biotech AB
B103: High-Throughput Antibody Screening of Plasma Cells with Xdrop, Presented by Barbara S., Samplix ApS
B104: Particles Identification: Challenges and Solutions, Presented by Elizabeth C., Sanofi
B105: Streamlining Immune Cell Profiling: Advanced Panel Design with Sartorius Antibodies and New iQue® HTS Platform, Presented by Helge S., Sartorius Lab Instruments GmbH & Co. KG
B106: Boosting Transient Protein Expression: A New Plug-and-Play Protocol for CHO Cells with FectoPRO and 4Cell CHO TF Medium, Presented by Dennis K., Sartorius Xell GmbH
B107: Accurate In Silico Prediction of pH-Dependent Antibody Binding Affinities Using Robust Physics-Based Methods, Presented by Esam A., Schroedinger GmbH
B108: Systematic Optimization of Expression and Purification Workflows for Diverse Membrane Proteins: From GPCRs and Ion Channels to Glycoprotein Receptors, Presented by Monika S., Selvita
B109: Rapid CAR Screening and CircRNA-Driven CAR-NK Cells for Persistent Shed-Resistant Immunotherapy, Presented by Jisu H., Seoul National University
B110: Targeting the sFasL-DR5 Axis with a Biparatopic Antibody to Overcome Treatment Resistance in Rheumatoid Arthritis, Presented by Yujin J., Seoul National University
B111: COIN: Confidence Score-Guided Distillation for Annotation-Free Cell Segmentation, Presented by Seo Jin L., Seoul National University
B112: Beyond Counts: Convolutional Neural Networks Enables Identification of Subvisible Particles, Presented by Pierre L., Servier
B113: The Roles of Cold Denaturation and Shear Stress in Protein Aggregation During Freeze-Thaw: A Downscale Study, Presented by Andreia D., Smartfreez
B114: Avoiding Mechanical Stresses of Freezing to Improve Stem Cell Viability and Functional Recovery, Presented by Rafaela N., Smartfreez
B115: NewPath ADC: A Novel Payload-Focused Approach to Next Generation ADC Development, Presented by Joshua G., Sygnature Discovery
B116: Cryo-EM for Structurally Enabled Development of Small Molecule Drugs and Therapeutic Antibodies Against GPCRs, Presented by Steven H., Sygnature Discovery
B117: Synthetic Genetic Elements for Improving Recombinant Protein Expression, Presented by Andy R., SynGenSys Ltd.
B118: INNObodies™: AI-Driven Design of Heavy-Chain Antibodies for Targeted Applications, Presented by Martin S., SynSilico B.V.
B119: Impact of Weak Vibration Generated by a Refrigerator on Protein Aggregation, Presented by Shinji K., Taiho Pharmaceutical Co., Ltd.
B120: Redirecting Neutrophil and Macrophage Cytotoxicity via CD89-Engaging Bispecific Antibodies, Presented by Felix M., Technical University of Darmstadt
B121: A Generic Strategy for the Conversion of Therapeutic mAbs into Immune Cell Recruiting Bispecifics, Presented by Paul P., Technical University of Darmstadt
B122: Protein Aggregation and Fibril Formation: Shear Stress into Context, Presented by Rene R., Technical University of Denmark
B123: Quality of Nested Ready-to-Use (RTU) Primary Packaging Material: A Case Study of Pre-Fillable Syringes for Intravitreal Drug Delivery, Presented by Jari A., ten23 health
B124: Disposable Mixing Systems for Biological Products: Evaluation of Shear Stress, Presented by Dilara A., ten23 health
B125: Development of a Protein-Free Feed System that Enhances Titer and Demonstrates Consistency in CHO-K1 Cell Lines, Presented by Madhavsai G., Thermo Fisher Scientific
B126: Automating the Expi293™ PRO Expression System for mAb and Fc Fusion Protein Production, Presented by Matt M., Thermo Fisher Scientific
B127: Navigating the Sequence Space: Machine Learning for Simultaneous Optimized Humanized Camelid Antibody, Presented by Mitsuo U., Tohoku University
B128: Ultra-Bright Labels for Better Molecular Diagnostics, Presented by Klaus W., Ultrabright Biotech
B129: Defensin-Based ACE2 Mimetics for Broad Spike Variant Binding and Antiviral Screening, Presented by Maria BM., Universidade do Estado de Santa Catarina
B130: Selection of Potent Antagonists of the Cannabinoid GPCR CB2R from a Constrained Peptide Library, Presented by David O., University College Dublin
B131: Genetic Engineering of Nanobody-Based Multispecific Conditional TNF Receptor Agonists, Presented by Isabell L., University Hospital Würzburg
B132: Z-Forge: An End-to-End De Novo Affibody Design Pipeline, Presented by Oliver W., University of Cambridge
B133: Enhancing the Transduction Efficiency of Lentiviral Vectors in CAR-T Cell Therapy Through an Optimization Workflow, Presented by Joao G., University of Lisbon
B134: Discovery of NSCLC-Specific Single Chain Antibodies Using a Target-Agnostic Approach, Presented by Mariana G., University of Malta
B135: Characterising the Reversible Self-Association of α-Chymotrypsinogen and the Relationship to Predicting Highly Concentrated Viscosity Behaviour, Presented by Mark O., University of Manchester
B136: Trispecific SEED Antibodies Engineered for Neutrophil-Mediated Cell Killing, Presented by Katharina S., University of Natural Resources and Life Sciences - BOKU
B137: Machine Learning–Guided Human VHH Antibody Development Using Mammalian Display Technology, Presented by Adeesha H., University of Turku
B138: Development of scFv and DARPin Binders Targeting CHO Cells from Synthetic Phage Display Libraries, Presented by Anastasiia K., University of Turku
B139: Disulfide Stabilized hu4D5 scFv-Fc Inhibits Growth of HER2+ Breast Cancer Cells Resistant to Trastuzumab, Presented by Susanna L., University of Turku
B140: Facilitating Pan-Alphavirus Immunity Through Antigen-Presenting Adapter Proteins for Nanoparticle Fusion, Presented by Gustavo A., Vanderbilt University
B141: Bi-Specific Antibody Generation - In House Study by Controlled Fab-Arm Exchange (cFAE), Presented by Paul W., Viva Biotech Ltd.
B142: Computational Design of IL-11 Inhibitor Miniproteins, Presented by Ambrus G., VRG Therapeutics
B143: CellVysion – Avidity Matters in Engineering Antibodies, Presented by Jos V., vYsens
B144: Increase the Expression by Designing DNA Templates in Cell-Free Protein Synthesis, Presented by Kohei U., Waseda University
B145: Orthogonal Approaches to Aggregation Risk Monitoring and Screening for Complex Biologics, Presented by Paul D., Waters Corporation
B146: Meeting the Demand for Deeper LC-MS Product Characterization: Enabling Enhanced MS Performance with Multi-Reflecting TOF Technology, Presented by Jonathan F., Waters Corporation
B147: Comprehensive LC-MS Analytical Assays for Antibody-Oligonucleotide Conjugate (AOC) and siRNA Linker-Payload Characterization, Presented by Nick P., Waters Corporation
B148: Engineering Bispecific T-Cell Engagers Against Cancer-Specific pHLA Class II Antigens, Presented by Andreas H. & Harvey C., Yellowstone Biosciences
B149: A Next-Generation Workflow for Safe TCR Mimic Antibody Discovery: The ValidaTe Platform, Presented by Oliver S., BioCopy GmbH
B150: Decoding the Antibody Repertoire for Diagnostics and Therapeutics with Mimotope Variation Analysis (MVA), Presented by Alex S., Protobios LLC